Skip to main content
. 2016 Apr 20;33(1):168–175. doi: 10.3904/kjim.2015.158

Table 2.

Characteristics of patients developed brain metastases

Characteristic Total (n = 67) EGFR MT (n = 27) EGFR WT (n = 40) p value
Sex 0.014
 Male 35 (52.2) 9 (33.3) 26 (65.0)
 Female 32 (47.8) 18 (66.6) 14 (35.0)
Age, yr 68 (41–85) 64 (45–83) 68 (41–85) 0.335
ECOG PS 0.040
 0–1 56 (83.6) 26 (96.3) 30 (75.0)
 2–3 11 (16.4) 1 (3.7) 10 (25.0)
Smoking history 0.013
 Never-smoker 31 (46.3) 17 (63.0) 14 (35.0)
 Former smoker 16 (23.9) 7 (25.9) 9 (22.5)
 Current smoker 20 (29.9) 3 (11.1) 17 (42.5)
Pathologic histology 0.085
 Adenocarcinoma 47 (70.1) 23 (85.2) 24 (60.0)
 Squamous 6 (9.0) 0 6 (15.0)
 Large cell 10 (14.9) 3 (11.1) 7 (17.5)
 Other 4 (6.0) 1 (3.7) 3 (7.5)
Symptoms of BM 0.803
 Absent 30 (44.8) 13 (48.1) 17 (42.5)
 Present 37 (55.2) 14 (51.9) 23 (57.5)
EGFR TKI treatment
 1st line 13 (48.1)
 2nd line 11 (40.7)
 3rd line 2 (7.4)
 None 1 (3.7)
Timing of BM 0.599
 Synchronous 47 (70.1) 20 (74.1) 27 (67.5)
 Metachronous 20 (29.9) 7 (25.9) 13 (32.5)
No. of lesions 0.741
 Single 19 (28.4) 6 (22.2) 13 (32.5)
 2–4 11 (16.4) 5 (18.5) 6 (15.0)
 ≥ 5 37 (55.2) 16 (59.3) 21 (52.5)
Local treatment of BM 0.896
 WBRT 37 (55.2) 15 (55.6) 22 (55.0)
 SRS 11 (16.4) 5 (18.5) 6 (15.0)
 Surgery 4 (6.0) 2 (7.4) 2 (5.0)
 None 15 (22.4) 5 (18.5) 10 (25.0)

Values are presented as number (%) or median (range).

EGFR, epidermal growth factor receptor; MT, mutation type; WT, wild type; ECOG PS, Eastern Cooperative Oncology Group Performance status; BM, brain metastasis; TKI, tyrosine kinase inhibitor; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery.